Inhaled study drug for adults with bronchiectasis
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication for adults with bronchiectasis, a lung condition that causes chronic cough and mucus. The goal is to see if the drug is safe and helpful in reducing symptoms and infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of bronchiectasis (a lung condition causing widened airways and excess mucus) from a CT scan, linked to a cause like COPD, cystic fibrosis, or other conditions.
- You need to produce sputum (phlegm) on a regular basis and be able to cough it up reliably during the study.
- Your lung function must be at least 40% of the predicted value, measured by a breathing test.
- You must have had at least one chest infection treated with antibiotics in the past 2 years.
- You need to avoid certain antibiotics and other inhaled therapies before and during the study.
- You must not have a history of certain infections (like Burkholderia, Aspergillus, or non-tuberculosis mycobacteria) within the past year or two.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests an inhaled medication for people with bronchiectasis, a lung condition causing chronic cough and mucus. It first checks safety in healthy volunteers, then studies how the drug works in people with bronchiectasis.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
Hear when a new Bronchiectasis Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.